Rapidly Advancing New Scientific Discoveries
to Transform the Way Cancer is Treated
|
Using its proprietary delivery system, TransCode is developing RNA therapeutics for the treatment of several solid tumor indications with its initial focus on tackling one of the most feared stages of cancer -- cancer progression or metastasis.
|
|
|
Power and Potential of RNA-based TherapiesThe power of RNA therapeutics lies in their ability to target any gene which enables rational and straightforward drug design. RNA-based therapeutics are highly selective to their targets, potentially making available a broad array of previously undruggable targets in cancer including metastasis.
|
TransCode Therapeutics believes it has overcome the barrier to harnessing
RNA technology for cancer treatment — targeting of RNA therapeutics to cancer cells
A small, non-coding microRNA called miRNA-10b, is shown to be the master regulator of metastasis in a range of solid tumors
Metastatic tumor cells are better equipped to safely travel to other parts of the body and develop metastases in organs different from the organ of origin
|
Cells in the primary tumor are known to upregulate miRNA-10b which allows metastatic cells to develop, detach, and migrate
TransCode’s TTX platform has the potential to treat a variety of
tumor indications through effective delivery and targeting |